Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma

Leukemia Research
Marc SorigueJosep-Maria Ribera

Abstract

Nephrotoxicity is a well-known side effect of platinum-based chemotherapy. We retrospectively assessed the incidence and prognostic impact of nephrotoxicity with ESHAP rescue chemotherapy in 74 lymphoma patients (61 aggressive lymphomas). A higher incidence of nephrotoxicity (estimated glomerular filtration rate <60mL/min) was found when ESHAP was administred on an outpatient vs. inpatient basis (14/39 vs. 4/35). Patients submitted to ASCT with renal failure had a lower overall survival (OS) than those with normal renal function (2-yr OS probability [95%CI]: 88% [77%-99%] vs. 50% [22%-78%]). Outpatient administration of ESHAP may not be optimal for all patients and the impact of ESHAP-induced renal failure on ASCT outcomes in lymphoma needs to be assessed in prospective studies.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Haematologica
José RodríguezGrupo Español de Linfomas/Trasplante Autólogo de Médula Osea, Spanish Lymphoma/Autologous Bone Marrow Transplant Study Group
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
John W Sweetenham, P W Johnson
European Journal of Cancer & Clinical Oncology
F Ries
British Journal of Hospital Medicine
B Leaker, H S Cairns
Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
Vit ProchazkaKarel Indrak
© 2022 Meta ULC. All rights reserved